Citryll is a private pharmaceutical company dedicated to the development and commercialization of antibody therapeutics that target the newly discovered biology of neutrophil extracellular traps (part of innate immunity), where neutrophils ‘unpack’ their chromatin in a catastrophic way, which ‘explodes’ the cell. This is designed to trap neighboring pathogens invading from the microbiome, but exacerbates tissue and organ damage in cases of chronic inflammation. The initial indication is SLE (Systemic Lupus Erythematosus).